Clinical Trial Update: N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and tolerability of a three-drug combination (irinotecan, temozolomide, and cefixime) in young patients with recurrent or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• CEFIXIME (cefixime)
• Irinotecan (Irinotecan)
• Temozolomide (Temozolomide)

Snippet

Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Conditions: Diarrhea, Drug/Agent Toxicity by Tissue/Organ | Phase 1 | Status: COMPLETED